Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.0
Journals
JPM
Special Issues
Urological Cancer: Clinical Advances in Personalized Therapy
share announcement

Urological Cancer: Clinical Advances in Personalized Therapy

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 25 March 2026 | Viewed by 2422

Special Issue Editors

Dr. Angelo Mottaran

E-Mail Website
Guest Editor
Division of Urology, IRCCS Azienda Ospedaliero—Universitaria di Bologna, 40138 Bologna, Italy
Interests: minimally invasive surgery; RARP; RAPN; RARC; prostate cancer; renal cancer; urothelial cancer; robotic platforms
Dr. Marco Paciotti

E-Mail Website
Guest Editor
Department of Urology, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: diagnosis and treatment of urologic malignancies; robotic surgery; surgical training
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, the field of urology has witnessed a transformative shift towards minimally invasive surgical techniques, with robot-assisted surgery at the forefront of this evolution. This innovation has expanded the scope of minimally invasive procedures, extending its applications from oncological treatments to the management of benign diseases. At the same time, significant development has occurred in terms of pharmacological approaches, with the advent of novel drugs designed to target various urologic malignancies with unprecedented precision.

Against this backdrop, we are excited to announce this Special Issue dedicated to showcasing the latest clinical advancements in pursuing personalized therapy for urological tumors. We invite contributions that not only highlight technological and therapeutic breakthroughs but also shed light on how these developments are paving the way for customized treatment plans tailored to each patient’s unique needs.

Dr. Angelo Mottaran
Dr. Marco Paciotti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • minimally invasive surgery
  • robot-assisted surgery
  • immunotherapy
  • prostate cancer
  • renal cancer
  • urothelial cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 418 KiB  
Article
Comparing Multigene Molecular Testing Results of MRI-Target Versus Systematic Prostate Needle Biopsies of Candidates for and Under Active Surveillance
by Nicholas J. Lanzotti, Chris Du, Julia Hall, Joseph Saba, Maria M. Picken and Gopal N. Gupta
J. Pers. Med. 2025, 15(7), 279; https://doi.org/10.3390/jpm15070279 - 1 Jul 2025
Viewed by 19
Abstract
Introduction: The multigene molecular testing of prostate cancer tissue after biopsy provides individualized information to guide further management. The utility of selective genetic testing for MRI-visible target versus systematic cancer in patients as well as during different time points of active surveillance (AS) [...] Read more.
Introduction: The multigene molecular testing of prostate cancer tissue after biopsy provides individualized information to guide further management. The utility of selective genetic testing for MRI-visible target versus systematic cancer in patients as well as during different time points of active surveillance (AS) is unknown. The objective of this study was to compare ProlarisTM results of MRI-target cancers versus systematic cancers on prostate needle biopsy as well as both during consideration for initial AS candidacy and candidacy for remaining on AS. Methods: Our prospectively maintained institutional multiparametric (mp) MRI prostate cancer active surveillance database (2013–2024) was queried for patients that underwent ProlarisTM genetic testing of positive biopsy cores. Baseline information for PSA, PSA density, and ProlarisTM calculated data were collected. Information on the timing of the Prolaris testing, defined as during the initial cancer diagnostic biopsy or on a subsequent confirmatory biopsy was collected. SPSS v29.0 was used to compare the selective ProlarisTM results of MRI-target cancers versus systematic cancers during different points of AS. Results: 264 patients with a ProlarisTM test were identified, 86 with MRI-target and 178 on systematic cancers. 182 ProlarisTM tests were sent on a diagnostic biopsy and 81 on a subsequent biopsy. Overall, MRI-target cancers had similar risk scores (3.23 vs. 3.14, p = 0.18). ProlarisTM scores were higher for GG2 systematic than GG1 target cancers (3.40 vs. 3.18, p = 0.023). The GG2 systematic lesion cohort also had higher predicted the 10-year disease-specific mortality (DSM) (3.40% vs. 2.30%, p < 0.01) and 10-year metastasis risk (1.90% vs. 1.20%, p = 0.013), and more aggressive recommended treatment. Analyses of the ProlarisTM results sent during a diagnostic biopsy yielded similar results. Finally, on an analysis of the ProlarisTM results sent during subsequent biopsy, a systematic GG2 biopsy was noted to have a higher 10-year DSM and metastasis rate, but similar risk scores and treatment recommendations. Conclusions: ProlarisTM tests can be sent at multiple time points of AS, and selectively for MRI-visible versus higher grade cancers. There is no consistent association between MRI-visible cancer and Prolaris risk profile. When utilizing multigene molecular testing in prostate cancer, each individual patient must be evaluated to decide the appropriate level of care. Full article
(This article belongs to the Special Issue Urological Cancer: Clinical Advances in Personalized Therapy)
►▼ Show Figures

Figure 1

Other

Jump to: Research

18 pages, 480 KiB  
Systematic Review
High-Intensity Focus Ultrasound Ablation in Prostate Cancer: A Systematic Review
by Che-Hsueh Yang, Daniela-Viviana Barbulescu, Lucian Marian, Min-Che Tung, Yen-Chuan Ou and Chi-Hsiang Wu
J. Pers. Med. 2024, 14(12), 1163; https://doi.org/10.3390/jpm14121163 - 20 Dec 2024
Cited by 2 | Viewed by 1901
Abstract
Background/Objectives: Prostate cancer (PCa) outcomes vary significantly across risk groups. In early-stage localized PCa, the functional outcomes following radical prostatectomy (RP) can be severe, prompting increased interest in focal therapy, particularly High-Intensity Focused Ultrasound (HIFU). This study is to summarize the current clinical [...] Read more.
Background/Objectives: Prostate cancer (PCa) outcomes vary significantly across risk groups. In early-stage localized PCa, the functional outcomes following radical prostatectomy (RP) can be severe, prompting increased interest in focal therapy, particularly High-Intensity Focused Ultrasound (HIFU). This study is to summarize the current clinical trials of HIFU on PCa. Methods: We reviewed clinical trials from major databases, including PubMed, MEDLINE, Scopus, and EMBASE, to summarize the current research on HIFU in PCa treatment. Results: The literature highlights that HIFU may offer superior functional outcomes, particularly in continence recovery, compared to RP and radiation therapy. However, the oncological efficacy of HIFU remains inadequately supported by high-quality studies. Focal and hemigland ablations carry a risk of residual significant cancer, necessitating comprehensive patient counseling before treatment. For post-HIFU monitoring, we recommend 3T magnetic resonance imaging (MRI) with biopsy at 6 to 12 months to reassess the cancer status. Biochemical recurrence should be defined using the Phoenix criteria, and PSMA PET/CT can be considered for identifying recurrence in biopsy-negative patients. Conclusions: Whole-gland ablation is recommended as the general approach, as it provides a lower PSA nadir and avoids the higher positive biopsy rates observed after focal and hemigland ablation in both treated and untreated lobes. Future study designs should address heterogeneity, including variations in recurrence definitions and surveillance strategies, to provide more robust evidence for HIFU’s oncological outcomes. Full article
(This article belongs to the Special Issue Urological Cancer: Clinical Advances in Personalized Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop